Johnson & Johnson faces claim by 3,000 in U.K. who say asbestos in talcum powder made them sick

Johnson & Johnson is facing a new, substantial legal claim in the U.K. valued at over £1 billion ($1.34 billion) from more than 3,000 individuals alleging its talcum powder caused cancer due to asbestos contamination, which the company purportedly knew about for decades. This U.K. lawsuit mirrors thousands of similar cases in the U.S., where J&J recently agreed to a $700 million settlement and faced a $966 million jury award. J&J has deflected responsibility to Kenvue, its former consumer health business, which denies the allegations, asserting product safety and compliance, but the ongoing litigation represents significant financial and reputational risk for both entities.

Analysis

Johnson & Johnson (JNJ) is confronting a significant new class-action lawsuit in the U.K. involving over 3,000 claimants seeking more than £1 billion ($1.34 billion) for alleged cancer causation by asbestos-contaminated talcum powder. This claim, covering 1965-2023, asserts J&J knowingly sold products with carcinogenic fibers for decades, echoing thousands of similar U.S. cases where J&J recently agreed to a $700 million settlement and faced a $966 million jury award.

J&J has largely shifted responsibility to Kenvue (KVUE), its former consumer health business, which retained liability for non-U.S./Canada talc litigation post-August 2023 separation. Kenvue denies the allegations, citing independent testing and regulatory compliance, while internal J&J memos from 1969 reportedly acknowledged potential safety concerns regarding tremolite in talc.

The U.K. lawsuit underscores historical industry lobbying against FDA regulation of asbestos in talc, despite known dangers. This ongoing litigation represents a substantial financial and reputational risk for both JNJ and KVUE, with the U.K. case being decided by a judge rather than a jury, potentially altering legal dynamics compared to U.S. outcomes.

Key Decisions for Investors

• Investors should closely monitor the financial and reputational impact of the U.K. talc litigation on both Johnson & Johnson (JNJ) and Kenvue (KVUE), given Kenvue's assumed liability for non-U.S./Canada cases and the £1 billion claim.
• Evaluate the potential for further legal costs and settlements to erode shareholder value, considering the historical U.S. legal precedents and the ongoing negative sentiment surrounding these claims.
• Assess the long-term brand implications for JNJ, even with the liability separation, as persistent litigation can affect consumer perception and market standing.